Dual Targeting of B7-H3 in metastatic prostate cancer
Official title: Project 2: Dual Targeting of B7-H3 in mCRPC
Funded at Johns Hopkins University · NIH-11418390 · Data updated 2026-11-12
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $382,083 |
| NIH project number | 5P50CA272391-03 |
| Project ID | NIH-11418390 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with metastatic castration-resistant prostate cancer who have progressed on standard therapies and meet specific safety criteria.
✕Less likely to help
Patients with certain intolerances or contraindications to antibody therapies or those who do not express target pathways may not benefit.
What this research studies
This project aims to test two B7-H3–targeted treatments in men with advanced prostate cancer. The study builds on prior experiences with Enoblituzumab and MGC018 to see if combining them is safe and can provoke immune and tumor-killing effects. Researchers will monitor safety, PSA levels, imaging results, and immune changes in the tumor microenvironment to understand how the treatments work. The focus is on translating this approach into meaningful benefits for patients who have progressed on standard therapies.
Why it matters
Potential benefit: If successful, patients may experience tumor shrinkage or stabilization and improved symptoms from a therapy tailored to their cancer biology.
How similar studies have gone: Prior Enoblituzumab experience and related ADCs provide a basis for potential benefit, though combination results in this setting are exploratory.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Pienta, Kenneth J. — Johns Hopkins University
- Study coordinator: Pienta, Kenneth J.
Related research
Other NIH-funded projects on the same topics.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Extending Benefit by Targeting Resistant Lesions in mCRPC
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
-
Liquid biopsy test to guide HER2-targeted therapy for advanced prostate cancer
A new liquid biopsy test using blood markers to pick and guide HER2-directed therapy for men with advanced, treatment-resistant prostate cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.